Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
105 studies found for:    Open Studies | "Pulmonary Fibrosis"
Show Display Options
Rank Status Study
21 Recruiting Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
22 Recruiting Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention:
23 Recruiting A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: KD025;   Drug: Standard of Care
24 Recruiting Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Pulmonary Fibrosis
Intervention:
25 Recruiting Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: ART-123;   Drug: Placebo
26 Recruiting Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
27 Recruiting Early Diagnosis of Pulmonary Fibrosis - Use of Biomarkers in Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
28 Recruiting Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Behavioral: Physical exercise training;   Behavioral: Cognitive exercise training
29 Not yet recruiting A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Valganciclovir;   Drug: Placebo
30 Recruiting 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
Condition: Pulmonary Fibrosis, Unspecified
Interventions: Drug: 68Ga-NOTA-PRGD2;   Device: PET/CT
31 Recruiting Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Cyclophosphamide;   Drug: Placebo;   Drug: Corticosteroid (prednisolone)
32 Recruiting A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: lebrikizumab;   Drug: pirfenidone;   Drug: placebo
33 Recruiting PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
34 Recruiting Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
35 Recruiting Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Nintedanib;   Drug: Pirfenidone
36 Recruiting Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Nintedanib;   Drug: Placebo;   Drug: Sildenafil
37 Recruiting Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: nintedanib;   Drug: placebo
38 Recruiting Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis
Intervention:
39 Recruiting STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Condition: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Drug: BG00011;   Drug: Placebo
40 Recruiting Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
Condition: Idiopathic Pulmonary Fibrosis (IPF)
Intervention: Drug: Dasatinib + Quercetin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.